Angiomyofibroblastoma of the right labia major
Editor, Angiomyofibroblastoma (AMFB) of the vulva was first advocated by Fletcher et al. in 1992 . [1] AMFB is a rare, benign mesenchymal tumor that occurs in the subcutaneous tissue of the vulva and vagina in women and the scrotum in men, and must be differentiated, especially from aggressive angiomyxoma because of its different biological behavior. Female patients are usually premenopausal and present with a vulval mass that is often diagnosed initially as a Bartholin's cyst. Histologically, the tumors are well-circumscribed and characterized by alternating hypo-and hypercellular areas with abundant thin-walled blood vessels. The tumor cells are bland and spindle-shaped or epitheloid and tend to concentrate around the vessels or cluster in small nests. [2] Immunoreactivity for both desmin and vimentin is detected in almost all tumor cells, which also reveal estrogen and progesterone receptors, but staining for cytokeratin is negative. [3] In this report, we describe a case of AMFB in a 41-year-old female patient. A 41-year-old female patient, single, presented with a painless mass of the right labia major, which has been noticed first by the patient 1 year previously. Examination revealed a well-circumscribed, mobile swelling located in the subcutaneous tissue of the right labia major. Ultrasonography demonstrated a soft tissue tumor with homogeneous echo and normal vascularity. The resected tumor had a well-circumscribed border brownish soft appearance measuring 3 × 2, 2 × 1, 8 cm. Its cut surface was solid, homogenous, myxoid-like with focal areas, and grayish in color [ Figure 1a ]. Microscopically, the mass consisted of spindled and plump oval stromal cells of fibroconnective tissue with edematous stroma and abundant vessels of various wall thickness [ Figure 1b ]. The tumor cells were focally clustered with Figure 1c ]. No mitotic or atypical cells were seen. Immunohistochemically, the stromal cells showed strong positivity for vimentin and desin [ Figure 2a and b], but were negative for CD34, CD31, factor Vlll, smooth muscle actin, S-100, and pan cytokeratin. İn addition to, the nucleus of the stromal cells showed positivity for estrogen and progesterone receptors. The final diagnosis was AMFB of the right labia major. This distinctive tumor was first delineated by Fletcher et al. in 1992, who described 10 cases involving the vulva [1] with only one case reporting a large pedunculated mass. There is a marked predilection for the female genital tract, predominantly the vulva, although rare cases have also been reported to arise in the scrotum and the inguinal area in males. [1] The patients ranged in age from 17 to 86 years (mean, 45 years). Our patient at 41-year-old is representative of this typical age range. They usually complain of a painless mass that has been present from a few weeks to up to 13 years. [4] Our patient presented with a painless mass of the right labia major, which has been noticed first by the patient 1 year previously. On gross examination, the tumors were well-circumscribed and ranged in size from 0.5 to 30 cm in maximal diameter (mean, 5.9 cm). They have a soft to rubbery consistency and a bulging, pink, and somewhat lobulated sectioned surface. [4] Our patient's tumor was a well-circumscribed border brownish soft appearance measuring 3 × 2, 2 × 1, 8 cm. The histogenesis of AMFB is unknown. It is believed that it originates from primitive mesenchymal cells. Microscopic examination confirms the well-demarcated nature of the lesion and shows alternating hypercellular and hypocellular edematous regions with abundant blood vessels. The cells tend to cluster around blood vessels, sometimes forming compact foci. [4] It is a slow growing tumor associated with the very low mitotic activity. There is minimal nuclear atypicality, and it can rarely undergo sarcomatous change. [5] Our patient was not seen mitotic or atypical cells. Although occasional cases recur locally, AMFBs generally behave in a benign fashion. The lesions can be treated easily by simple excision as our patient. The main differential diagnosis of AMFB is aggressive angiomyxoma, which is distinctive locally aggressive fibromyxoid tumor of the pelvic and genital soft tissues. In contrast to AMFB aggressive angiomyxoma is a deeply seated tumor with infiltrative growth pattern, which frequently results in entrapment of mucosal glands and nerves. Aggressive angiomyxoma is poorly circumscribed, and the stroma cells are a short spindle or stellate shaped within a loose myxoid matrix. The hyaluronic acid-rich stroma also contrasts with the absence of stromal mucin in AMFB. The key microscopic features are of aggressive angiomyxoma are medium-to large-sized vessels with a muscularized, thick, and hyalinized wall. Whereas, the blood vessels of AMFB are thin-walled, venular or capillary-sized. Our case was not observed any prominent hyalinization and hypertrophy in the vessel walls, or mucin in the stroma. In contrast, the blood vessels of our case are thin-walled, venular, or capillary-sized. The immunohistochemical profile of the AMFBs reported is almost uniformly positive for vimentin and frequently positive for desmin. The tumor cells demonstrate variable expression for smooth muscle actin and are frequently immunoreactive for progesterone and estrogen receptors, suggestive of the sex steroid dependency of this tumor. AMFBs are typically negative for CD34 but may demonstrate some reactivity about vessels, as the vessels are typically reactive. [6] İn our case, the stromal cells showed strong positivity for vimentin and desrnin, but the stromal cells were negative for CD34, CD31, factor Vlll, smooth muscle actin, S-100, and pan cytokeratin. İn addition to, nucleus of the stromal cells showed positivity for estrogen and progesterone receptors. AMFB do not infiltrate deep structures, and wide excision is recommended in all cases.
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Biphenotypic extramedullary blast crisis with MLL gene rearrangement in a case of chronic myeloid leukemia following Dasatinib therapy: An unusual case
Editor, Chronic myeloid leukemia (CML) is the most common myeloproliferative neoplasm. It originates from abnormal pluripotent stem cell, and its hallmark is Philadelphia (Ph) chromosome or BCR-ABL fusion gene. [1] Though the majority of the cases present in the chronic phase of the disease, 5-10% of the cases present in accelerated phase or blast crisis at diagnosis. Bone marrow, peripheral blood, liver, and spleen are common sites of involvement by this leukemia in the chronic phase; however, during blast crisis, blast can infiltrate skin, lymph node, soft tissue, and central nervous system (CNS). Although CML is very responsive to the tyrosine kinase inhibitors (TKI), with response rates in the chronic phase of >90%, response rates for patients with CML in accelerated phase and blast crisis are lower. Imatinib was a boon for CML patients; however, due to poor blood-brain barrier (BBB) permeability, it could not reduce the risk of CNS relapse.
Second generation TKI such as Dasatinib has better CNS penetration. This report presents a case of CML in myeloid blast crisis, which attained complete molecular response (CMR) with Dasatinib therapy, and later developed isolated CNS relapse with biphenotypic blast and MLL gene rearrangement.
A 68-year-old diabetic male patient presented with fever and weakness. On examination, splenomegaly was noted. Hemogram revealed Hb 9.4 g/dl, platelet count 58 × 10 9 /l, and leukocyte count 119 × 10 9 /l. Peripheral smear showed 25% blast with basophilia, eosinophilia, and shift to left in granulocytic cells. Bone marrow examination showed 54% blast cells and few myeloid precursors along with eosinophilic prominence [ Figure 1a ]. Flow cytometric immunophenotype of bone marrow revealed ~41% myeloid blast expressing CD34, CD38, human leukocyte antigen (HLA)-DR, CD117, CD13, CD 33, cMPO, and aberrant CD19. Blasts were negative for CD 79a. Karyotyping of bone marrow revealed 46 XY, t(9;22)(q34;q11.2) in all 20 metaphase analyzed [ Figure 1b ]. Qualitative polymerase chain reaction (PCR) was positive for BCR-ABL major type (p210). Hence, patient was diagnosed as a case of CML in myeloid blast crisis. The patient received induction regime followed by consolidation therapy. Dasatinib was also added. He achieved CMR in 4 months as confirmed by quantitative RT-PCR and was maintained on Dasatinib therapy. Considering the age of the patient, transplant was not an option. The patient was on regular follow-up and was asymptomatic for 19 months.
In December 2014, the patient presented with headache, vertigo, and vomiting. Hemogram was within normal limits; bone marrow was morphologically in remission and was negative for minimal residual disease. Lumbar puncture was 
